English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the early 1980s, we assiduously followed management guidelines advocating intravenous heparin for patients within 2 months of transient ischemic attack (TIA) and for most patients with acute ischemic stroke. Heparin flowed freely; there were always 2 to 3 patients receiving it on the neurology ward and a dozen partial thromboplastin times were urgently checked each day. Times have changed. High standards of evidence are expected to support management recommendations, grounded firmly in randomized clinical trials rather than traditional GOBSAT methods (Good Old Boys Sat At Table).1 Nine randomized trials have tested intravenous unfractionated heparin or related agents in acute stroke.2 Critical analysis of the accumulated evidence does “not support the routine use of any type of anticoagulant in acute ischemic stroke.”2 It is clear that intravenous heparin …

Do We Really Need a Better Way to Give Heparin in Acute Cerebral Ischemia?